Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma (CONFIRM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03836014
Recruitment Status : Recruiting
First Posted : February 11, 2019
Last Update Posted : November 27, 2019
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

The incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of care has improved the outcome for patients with multiple myeloma (MM) over the past 10 years. However, most patients (>85%) still eventually relapse around 3-4 years after diagnosis, and ultimately die of their disease, despite salvage therapies. Relapse can occur even when complete remission is achieved after first-line therapy.

Currently, daratumumab (Dara) is approved by the american FDA and EMA in combination with lenalidomide (Len) and dexamethasone (Dex) or bortezomib and Dex for the treatment of MM patients who have received at least one prior therapy. Therefore, the Dara-Len-Dex combination is likely to become the most widely used standard of care regimen for MM at the time of first relapse.

However, although approval of the latter combination is meant for until disease progression (PD) ("continuous therapy") (CT), the actual optimal duration of relapse treatment is still unknown. Of note, many experts advocate that a "fixed duration" of therapy should be favored, especially if one can show that CT does not translate into a significant overall survival (OS) benefit. As a matter of fact, given the extremely high cost of such novel agents (>100 KEuros/year/patient), the pharmacoeconomic consequences of a "continuous" versus "fixed" duration therapy are also of utmost importance.

Based on this background, the investigator propose to conduct a non-inferiority phase III randomized, multicenter, open label trial for treatment of MM at first relapse, comparing the Dara-Len-Dex combination administered continuously until PD, versus a fixed duration of 24 months. The choice of this duration is justified by the currently available evidence with respect to achievement of a plateau in terms of deep disease response, patients' compliance, and physicians' preference according to different surveys. The primary objective of this study is to estimate the OS rate at 4 years after diagnosis of relapse and initiation of salvage therapy. The primary endpoint is OS at 4 years after randomization. The analysis will be performed on both per-protocol and intent-to-treat sets of patients.


Condition or disease Intervention/treatment Phase
Multiple Myeloma in Relapse Combination Product: Daratumumab/Lenalidomide/Dexamethasone for 24 months Combination Product: Daratumumab/Lenalidomide/Dexamethasone until progression Phase 3

Detailed Description:

MM is a B cells malignancy, and is one of the most frequent primary neoplasms of the bone marrow. The fundamental pathology is an expansion of a single clone of plasma cells that produce monoclonal immunoglobulin (M-proteins) and replace normal bone marrow. Although the etiology of myeloma is not known, several studies have shown that myeloma cells acquire certain genetic changes that allow for uncontrolled growth, migration, and protection from apoptosis.

The incidence of MM in Europe is 6.0 cases per 100,000 per year, with a median age at diagnosis between 63 and 70 years; the mortality is 4.1 cases per 100,000 per year.

Dara is a human IgG1ĸ monoclonal antibody that binds with high affinity to a unique epitope on CD38, a transmembrane glycoprotein. It is a targeted immunotherapy directed towards tumor cells that express high levels of CD38, such as plasma cells from patients with MM. This target is distinct from those of other approved agents for MM therapy. Darashowed promising efficacy alone and with Len and Den in a phase 1-2 study involving patients with relapsed or refractory MM. Subsequently, a phase 3 trial randomized 569 MM patients to receive Len and Den (Len-Dex; control group) or in combination with Dara (Dara-Len-Dex group) With a median follow-up of 25.4 months, progression-free survival was significantly prolonged in the Dara-Len-Dex group (median not reached versus 17.5 months in the control group; HR, 0.41; 95% CI, 0.31-0.53; P <0.0001). A significantly higher rate of overall response was observed in the Dara-Len-Dex group than in the control group (93% vs. 76%, P<0.0001), as was a higher rate of complete response or better (51% vs. 21%, P<0.0001). Furthermore, the rates of treatment discontinuation owing to adverse events were low and similar in the two groups.

The investigator propose to conduct a non-inferiority phase III randomized, multicenter, open label trial for treatment of MM at first relapse, comparing the Dara-Len-Dex combination administered continuously until PD, versus a fixed duration of 24 months. The choice of this duration is justified by the currently available evidence with respect to achievement of a plateau in terms of deep disease response, patients' compliance, and physicians' preference according to different surveys. As a matter of fact, given the extremely high cost of such novel agents (>100 KEuros/year/patient), the pharmacoeconomic consequences of a "continuous" versus "fixed" duration therapy are also of utmost importance.

Dosage, route of administration and administration schedule of the medications prescribed are in accordance with the FDA and EMEA authorization in MM first relapse. Only the duration of combination is compared. One group of patient will receive the Dara-Len-Dex combination until PD in accordance with the FDA and EMEA authorization in MM first relapse (standard of care). The experimental group will receive the Dara-Len-Dex combination for up to 24 months. This shorter duration of treatment (24 months) is justified by the currently available evidence with respect to achievement of a plateau in terms of deep disease response, patients' compliance, and physicians' preference according to different surveys.

The aim of the current protocol is to investigate whether a fixed duration of treatment (24 months) with the Dara-Len-Dex combination is not inferior to the continuous administration of the combination until PD. In this study some patients may have a similar OS while receiving a shorter duration of treatment. This study may allow to deliver a shorter duration of therapy for the treatment of MM at first relapse.

The foreseeable risks are those of an earlier relapse in patients receiving a fixed duration of Dara-Len-Dex combination compare to the situation where they would have received the treatment until PD.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 434 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center Phase III Randomized Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Actual Study Start Date : July 25, 2019
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2025


Arm Intervention/treatment
Experimental: Fixed duration therapy for 24 months.
Daratumumab, Lenalidomide, Dexamethasone
Combination Product: Daratumumab/Lenalidomide/Dexamethasone for 24 months

Conditioning regimen: 16 mg/kg IV :

  • Weekly (Cycles 1 and C2)
  • Every two weeks (C3 to C6)
  • Monthly from C7 up to 24 months in total (Arm 1)

Infusion reaction prophylaxis :

  • Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion
  • An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion
  • Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.

Lenalidomide:

Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle up to 24 months in total (Arm 1)

Dexamethasone:

Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle up to 24 months in total (Arm 1)


Active Comparator: Continuous therapy
Daratumumab, Lenalidomide, Dexamethasone
Combination Product: Daratumumab/Lenalidomide/Dexamethasone until progression

Conditioning regimen: 16 mg/kg IV :

  • Weekly (Cycles 1 and C2)
  • Every two weeks (C3 to C6)
  • Monthly from C7 until disease progression (Arm 2).

Infusion reaction prophylaxis :

  • Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion
  • An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion
  • Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.

Lenalidomide:

Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle until disease progression (Arm 2).

Dexamethasone:

Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle until disease progression (Arm 2).





Primary Outcome Measures :
  1. overall survival [ Time Frame: 4 years after randomization ]
    Overall survival (OS) is defined as the time between randomization and death due to any cause. Patients, who die, regardless of the cause of death, will be considered to have had an event even if they were lost to follow-up for an extended time. All subjects who are lost to follow-up prior to the end of the trial or who are withdrawn from the trial will be censored at the last available date the subject is known to be alive


Secondary Outcome Measures :
  1. Response rate [ Time Frame: Within the 4 years after randomization ]
    Best response rate obtain at any time within 4 years after randomization. Assessment of the International Myeloma Working Group uniform response criteria

  2. overall response rate (ORR) [ Time Frame: assessed monthly from Randomization until PD, (approximately up to 3 years). ]
    disease evaluation will be assessed monthly until disease progression. ORR and will be calculated as the number of responders (at least partial response PR) divided by the number of subjects in the ITT population

  3. Progression free survival (PFS) [ Time Frame: at 4 years after randomization and initiation of salvage therapy ]
    PFS will be calculated as the months between the randomization and disease progression based on IMWG criteria or death on study, whichever occurred earlier. Disease evaluation will be assessed monthly until disease progression or death.

  4. Incidence of adverse events. [ Time Frame: within the 4 years after randomization ]
    Descriptive statistics of cumulative dose, relative dose intensity, dose reduction and reason for dose reduction will be presented by treatment arm.

  5. Quality of Life (QoL) [ Time Frame: within the 4 years after randomization ]
    Evaluation by EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30)

  6. Quality of Life (QoL) [ Time Frame: within the 4 years after randomization ]
    Evaluation by EQ-5D 5L (EuroQol - five dimension - five levels).

  7. Incremental cost-effectiveness ratios [ Time Frame: during the 4 years after randomization ]
    expressed in cost per quality adjusted life year (QALY) gained, in cost per Life Year Gained, and in cost per progression free year gained



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult patients (≥ 18 years old)
  2. Documented MM in relapse according to standard criteria and requiring initiation of a first line salvage therapy.
  3. Subject must have received one prior line of therapy for MM.
  4. Subject must have achieved a response (PR or better) to the prior regimen.
  5. Subject must have an ECOG Performance Status score of 0, 1, or 2.
  6. For subjects experiencing toxicities resulting from previous therapy (including peripheral neuropathy), the toxicities must have been resolved or stabilized.
  7. Signed informed consent
  8. Affiliation to a social security system or equivalent (recipient or assign)
  9. Effective method of contraception for the duration of treatment and 3 months after the last dose for women of childbearing age and men with a partner of childbearing age:

    • Progestin-only pill associated with inhibition of ovulation
    • Hormonal methods of contraception, including oral contraceptive pills containing a combination of estrogen + progesterone, vaginal ring, injectables, implants and intrauterine devices (IUDs)
    • non-hormonal IUD
    • Bilateral tubal occlusion
    • Vasectomized partner with documented azoospermia 90 days after procedure and who received a medical assessment of surgical success
    • Intrauterine hormone release system (IUS)
    • Complete Abstinence: Complete abstinence is defined as the complete avoidance of heterosexual intercourse. Complete abstinence is an acceptable form of contraception for all study drugs and must be used throughout the duration of the study and for the duration of time as specified above. It is not necessary to use any other method of contraception when complete abstinence is elected. Acceptable alternate methods of highly effective contraception must be discussed in the event that the subject chooses to forego complete abstinence.

Exclusion Criteria:

  1. Evidence of refractoriness or intolerance to lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody). If previously treated with a lenalidomide or daratumumab-containing regimen, the subject is excluded if he or she:

    • Discontinued due to any severe adverse event related to prior lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody) treatment, or
    • If, at any time point, the subject was refractory to any dose of lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody). Refractoriness to lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody) is defined either as:

      • Subjects whose disease progressed within 60 days of lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody) administration; or
      • Subjects whose disease is nonresponsive while on lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody). Nonresponsive disease is defined as either failure to achieve at least a minimal response or development of progressive disease while on lenalidomide and/or daratumumab (or another anti CD38 monoclonal antibody).
  2. Subject has received an allogenic stem cell transplant (regardless of timing).
  3. Subjects planning to undergo a stem cell transplant prior to progression of disease on this study, ie, these subjects should not be enrolled in order to reduce disease burden prior to transplant.
  4. Subject has a history of malignancy (other than MM) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator is considered cured with minimal risk of recurrence within 3 years).
  5. Subject has known MM meningeal involvement.
  6. Subject has plasma cell leukemia (>2.0 × 109/L circulating plasma cells by standard differential) or Waldenström's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or amyloidosis.
  7. Subject has any concurrent medical condition or disease (eg, active systemic infection) that is likely to interfere with study procedures or results, or that, in the opinion, of the investigator would constitute a hazard for participating in this study.
  8. Subject has known uncontrolled chronic obstructive pulmonary disease (COPD)
  9. Subject has clinically significant cardiac disease.
  10. Subject is known to be seropositive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
  11. Creatinine clearance ≤30 mL/min (MDRD method) (lenalidomide dose adjustment will be considered for subjects with creatinine clearance 30-60 mL/min).
  12. Hypersensitivity to the active substance or to any of the excipients
  13. Pregnancy or lactation women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03836014


Contacts
Layout table for location contacts
Contact: Mohamad Mohty, PU-PH 01 49 28 26 20 mohamad.mohty@inserm.fr
Contact: Florent Malard, MD 01 48 28 09 68 malardf@yahoo.fr

Locations
Layout table for location information
France
Saint Antoine Hospital - Hematology Department Recruiting
Paris, France, 75012
Contact: Mohamad MOHTY, PhD    01 49 28 26 20 ext +33    mohamad.mohty@inserm.fr   
Contact: Floarent Malard, MCU-PH    01 48 28 09 68 ext +33    malardf@yahoo.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Layout table for investigator information
Principal Investigator: Mohamad Mohty, PU-PH Assistance Publique - Hôpitaux de Paris

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT03836014     History of Changes
Other Study ID Numbers: D20180138
2016-002129-12 ( EudraCT Number )
First Posted: February 11, 2019    Key Record Dates
Last Update Posted: November 27, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Multiple myeloma
Relapse
daratumumab,
lenalidomide
dexamethasone
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Daratumumab
Neoplasms, Plasma Cell
Recurrence
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Disease Attributes
Pathologic Processes
Dexamethasone
Dexamethasone acetate
Lenalidomide
BB 1101
Antibodies, Monoclonal
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids